MG-132

Catalog No.S2619

MG-132 is an inhibitor of proteasome with IC50 of 100 nM in a cell-free assay, and also inhibits calpain with IC50 of 1.2 μM.

Price Stock Quantity  
USD 100 In stock
USD 50 In stock
USD 170 In stock
USD 470 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

MG-132 Chemical Structure

MG-132 Chemical Structure
Molecular Weight: 475.62

Validation & Quality Control

Cited by 43 publications:

9 customer reviews :

Quality Control & MSDS

Related Compound Libraries

MG-132 is available in the following compound libraries:

Proteasome Inhibitors with Unique Features

Product Information

  • Compare Proteasome Inhibitors
    Compare Proteasome Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description MG-132 is an inhibitor of proteasome with IC50 of 100 nM in a cell-free assay, and also inhibits calpain with IC50 of 1.2 μM.
Targets Proteasome [1]
(Cell-free assay)
IC50 100 nM
In vitro MG-132 displays >1000 times more activity than ZLLal in inhibiting the ZLLL-MCA-degrading activity of 20S proteasome with IC50 of 100 nM versus 110 μM. MG-132 also inhibits calpain with IC50 of 1.2 μM. MG-132 induces neurite outgrowth in PC12 cells at an optimal concentration of 20 nM, displaying 500 times more potency than ZLLal. [1] MG-132 (10 μM) potently inhibits TNF-α-induced NF-κB activation, interleukin-8 (IL-8) gene transcription, and IL-8 protein release in A549 cells by inhibition of proteasome-mediated IκBα degradation. [2] MG-132 treatment potently induces p53-dependent apoptosis in KIM-2 cells by 26S proteasome inhibition. [3] Unlike BzLLLCOCHO or PS-341, MG-132 treatment results in weak inhibition of the chymotrypsinlike (CT-L) and peptidylglutamyl peptide hydrolysing (PGPH) activities of the 26S proteasome, whereas multiple myeloma cells (U266 and OPM-2) are more sensitive to induction of apoptosis by MG-132 than BzLLLCOCHO. [4] MG-132 (1 μM) sensitizes TRAIL-resistant prostate cancer cells by activating the AP-1 family members c-Fos and c-Jun, which, in turn, repress the antiapoptotic molecule c-FLIP(L). [5] MG-132 significantly enhances the ability of inositol hexakisphosphate (IP6) to reduce cellular metabolic activity in both PC3 and DU145 androgen-independent prostate cancer (AIPCa) cell lines. [6]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
LPS-stimulated RAW264.7 cellsNI\YVnhHfW6ldHnvckBCe3OjeR?=M{LJbFI2KM7:TR?=NX33NItSTE2VTx?=NGXM[nRKdmirYnn0d{BvcXS{aXOgc5hq\GVicILv[JVkfGmxbjD3bZRpKEmFNUCgc4YhOC5zIN88US=>NF72NIczPDZ7N{S5Oi=>
HL-60NEC5cY5EgXSxdH;4bYMhSXO|YYm=NWr4fYI5PDBizszNMl\qOFghcA>?MoTnSG1UVw>?NWrSWGNWUUN3MEyxNEDPxE1?M3fQc|I1Pjl5NEm2
SMMC-7721MUHDfZRwfG:6aXOgRZN{[Xl?MUO0NEDPxE1?MWW0PEBpMU\EUXNQM3HnT2lEPTB;Nz6xJO69VQ>?NFfE[YYzPDZ7N{S5Oi=>
A-549M4DVZWN6fG:2b4jpZ{BCe3OjeR?=NYnlcm85PDBizszNMn\5OFghcA>?MXrEUXNQM3fvb2lEPTB:MUCg{txONVu4bGVEOjR4OUe0PVY>
MCF-7NIjtUVREgXSxdH;4bYMhSXO|YYm=NVvxXZd3PDBizszNM4LMdlQ5KGh?MoTWSG1UVw>?NILnRmZKSzVyPUeuN{DPxE1?MXGyOFY6PzR7Nh?=
SW-480NFfueGtEgXSxdH;4bYMhSXO|YYm=MYC0NEDPxE1?NGnvTFI1QCCqNYizbJFTTE2VTx?=M3G3emlEPTB;NDFOwG0>NF\CcXczPDZ7N{S5Oi=>
NCI-H929M{fw[GN6fG:2b4jpZ{BCe3OjeR?=M1TqW|Eh|ryPMlX4O|IhcA>?NUnsN4RuTE2VTx?=NHWwbYhKSzVyPUCuNVch|ryPMo[wNlQ3OjVyOEi=
293TM3q4WmN6fG:2b4jpZ{BCe3OjeR?=NUDDPYFzOTBizszNMVW3NkBpNX3JSWM3TE2VTx?=MXnJR|UxRDJizszNNWPTS5kyOjR4MkWwPFg>
293TNWq5NmQ2TnWwY4Tpc44hSXO|YYm=NH;uO4IyOCEQvF2=MkXINlQhcA>?NEnwZnhFVVORMnrEUY9l\XKjdHXsfUBqdmS3Y3XzJIhm[XRvc3jvZ4shKA>?NELEdWwzPDZ{NUC4PC=>
HeLaNF\uN4VMcW6jc3WgRZN{[Xl?MmLGNVAh|ryPNXPzRnc2OSCqMnnwSG1UVw>?MU\JcoR2[2W|IGDBVnAh[2ynYY\h[4Uh[nliaX7obYJqfGmwZzDwdo9{\WG|b33lJIFkfGm4aYT5NV[5dY9NOjR|MkG4N|M>
MDA-MB-231NGnjR5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFT3dYEyKM7:TR?=NVjRc3pXPzJiaB?=MoPvSG1UVw>?M3[0TGlEPTB;MD6xPEDPxE1?MYOyOFE2OzJyNh?=
MCF-7NEjhUIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFXnW4gyKM7:TR?=M{TyT|czKGh?MlTlSG1UVw>?NHnqUZZKSzVyPUCuNVMh|ryPNFvLN5UzPDF3M{KwOi=>
MCF10AMlTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4C0WFEh|ryPMVu3NkBpM4mxfWROW09?M2G5R2lEPTB;MD6yPUDPxE1?M2HqS|I1OTV|MkC2
HEK-293NV3FWJNwU2mwYYPlJGF{e2G7Ml7QNkBidmRiMkCg{txONV;HToxuOiCqNIPuTpJFVVORM1fJdWlvcGmkaYTzJGNpXC2OIHHjeIl3cXS7IIfpeIghUUN3MDDv[kA6KG6PIB?=MmTNNlM2PDB5OUC=
Calu6MWjGeY5kfGmxbjDBd5NigQ>?NWnFV2FLOTBizszNM3HvTFE5KGh?NEix[JpFVVORNEXQPHZUcWewaX\pZ4FvfGy7IHHjZ5VufWyjdHXzJIZz[XSjeHnuJJBz\WO3coPvdi=>NUDaWJd1OjN3ME[0PFY>
IFN-gamma-induced RAW264.7MmH0SpVv[3Srb36gRZN{[Xl?NUi3OHlZTE2VTx?=MYfJcohq[mm2czDubZRzcWNib4jp[IUheHKxZIXjeIlwdiC5aYToJGlEPTBib3[gNE4xPzdizszNNVXlXHhqOjJ{N{eyO|c>
IPC227FMnnZR5l1d3SxeHnjJGF{e2G7NI\BRWUyKM7:TR?=MU[0PEBpNFK4SYNFVVORNXXTblI6UUN3ME2wMlA4PyEQvF2=NGTUeWIzOTl{NEWyPC=>
Hepa-1c1c7Mnf1SpVv[3Srb36gRZN{[Xl?NYDPWpR{OjVizszNNWHrT3pJPiCqNFGxTVRFVVORNXfOZ3Z1UW6lcnXhd4V{KE6{ZkKgdJJwfGWrbjDs[ZZmdA>?M{\4dlIxOzl{NUS0
COS-7NFjwTXlEgXSxdH;4bYMhSXO|YYm=MYqxNEDPxE1?MoPYSG1UVw>?M3vqPWlEPTB:MUCg{txONHLC[IcyQDB6OEC5Oy=>
HuH-7Mn\uR5l1d3SxeHnjJGF{e2G7M{\TZVExKM7:TR?=MXLEUXNQMnrvTWM2ODxzMDFOwG0>M{f4UFE5ODh6MEm3
OCI-Ly3NIjWV2pHfW6ldHnvckBCe3OjeR?=M{XwfVExKM7:TdMgM4j1UVQhcA>?MkfKSG1UVw>?MXHJcoR2[2W|IHj1cYFvKEmtYYDwZWJidHCqYTDzeIFjcWyrenH0bY9vKHerdHigSWM2OCCxZjCxJO69VQ>?MnmwNVgxOjRzMUO=
A2780 cDDPMWfBdI9xfG:|aYOgRZN{[Xl?NXvUVng{OjRiaB?=NHnVUXZFVVORNF\CbmxKdmS3Y3XzJIFxd3C2b4Ppd{BjgSCrbnjpZol1cW6pIGDUSW4h\GWpcnHkZZRqd25?M3;6S|E4Pjh2MEG4
LPS-stimulated RAW264.7 cellsMXjGeY5kfGmxbjDBd5NigQ>?MoK3SG1UVw>?MWrJcohq[mm2czDOSk1s[XCyYVKgSG5CKGKrbnTpcoc>NV3zVXE3OTd2MEeyO|c>
PC12M37WbGZ2dmO2aX;uJGF{e2G7MYOxNFAh|ryPwrC=MnHHNlQhcA>?MkXISG1UVw>?M1y1O2lvcGmkaYTzJFYuV0iGQT2gZY5lKEh{T{KtbY5lfWOnZDDjfZRwfG:6aXPpeJk>NXvYWmtlOTdzNUi0OVQ>
PC3NEfRc5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3XTbFIxKM7:TR?=NHHtU|Y1QCCqMnnZSG1UVw>?Mn6yTWM2OD1yLk[g{txOMUmxOlY5PjV|Nx?=
LP-1MlrPRZBweHSxc3nzJGF{e2G7MonCN|AxKG6PM4jKdVI1KGh?NInjeolFVVORM4fPS2lv\HWlZYOgZZBweHSxc3nzJIJ6KGmwY4LlZZNqdmdiY3zlZZZm\CCSQWLQJIxmfmWuIHHu[EBz\WS3Y3nu[{BO[2xvMTDwdo91\WmwIHzleoVtM2H6WVE2QTV6NUi5
ES6MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF;6SHNKSzVyPUCuNFE{ODZizszNMWLTRW5ITVJ?
A101DMonsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYfjXYg3UUN3ME2wMlA{Ojd7IN88US=>MXnTRW5ITVJ?
OCUB-MM2TtdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NE\2W|dKSzVyPUCuNFM4OzdizszNNWrsO|JXW0GQR1XS
LB2518-MELNFzjWmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUSzU|B4UUN3ME2wMlA{PzZizszNNXH0W|YxW0GQR1XS
SH-4NH[0[IVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NG\hXmpKSzVyPUCuNFQ{OSEQvF2=NHy0TJpUSU6JRWK=
KNS-42MofFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoH0TWM2OD1yLkC0OFQyKM7:TR?=MlzwV2FPT0WU
DSH1NW\uXFVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHzhPIxKSzVyPUCuNFUzQDlizszNM2HuTnNCVkeHUh?=
NTERA-S-cl-D1NFPR[lJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mke2TWM2OD1yLkC1O|czKM7:TR?=MV7TRW5ITVJ?
D-542MGNX;BSmtDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4S0U2lEPTB;MD6wOVk2PyEQvF2=MnH2V2FPT0WU
KS-1M4j3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3vQeGlEPTB;MD6wOlQ2QCEQvF2=NX;4PIlIW0GQR1XS
BL-41NFLpNGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NE\5WIxKSzVyPUCuNFY6PDdizszNNF6wOlBUSU6JRWK=
LXF-289M4Dofmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWHJR|UxRTBwMEewOlYh|ryPNHHWeGFUSU6JRWK=
D-247MGNHPuVFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF\ZO|JKSzVyPUCuNFczODlizszNMo\BV2FPT0WU
MMAC-SFMmfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYnJR|UxRTBwMEeyOlgh|ryPMmW1V2FPT0WU
CP66-MELNU[xXld4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4LUPWlEPTB;MD6wO|Uh|ryPMXzTRW5ITVJ?
LB771-HNCMnrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVTJR|UxRTBwMEiwN|Yh|ryPMl62V2FPT0WU
no-10Mn65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn;YTWM2OD1yLkC4PVA6KM7:TR?=NWfpeJM1W0GQR1XS
A388MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXnJR|UxRTBwMEmwOlUh|ryPMXzTRW5ITVJ?
OPM-2NUnyZXE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{PO[mlEPTB;MD6xNFQ4PCEQvF2=M3XwWXNCVkeHUh?=
OVCAR-4M1zLZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmX2TWM2OD1yLkGwPVM5KM7:TR?=MlfWV2FPT0WU
HOP-62M4K3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MonoTWM2OD1yLkGwPVQ6KM7:TR?=MVvTRW5ITVJ?
ML-2NWDjfJNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXfJR|UxRTBwMUG4NFYh|ryPMXrTRW5ITVJ?
UACC-257MlLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUDKOY5vUUN3ME2wMlEyQTJ5IN88US=>M3\LNXNCVkeHUh?=
NEC8MlPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXm0OnpHUUN3ME2wMlEyQTl3IN88US=>MnnhV2FPT0WU
ONS-76NFrVS3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYfLb3VGUUN3ME2wMlEzQTN3IN88US=>MVXTRW5ITVJ?
KE-37M3fEdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEP5TVFKSzVyPUCuNVMzPzhizszNMlPZV2FPT0WU
HT-144MmrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3XEe2lEPTB;MD6xN|g6PSEQvF2=M3jCbHNCVkeHUh?=
LB2241-RCCMWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3zIdGlEPTB;MD6xOFI1PyEQvF2=M4j2WnNCVkeHUh?=
TE-5NVT4dm1VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWfJR|UxRTBwMUSyO|gh|ryPMYXTRW5ITVJ?
KINGS-1M{PiTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYjYdpp3UUN3ME2wMlE1PzlizszNMn\MV2FPT0WU
NCI-H69M4Hwd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NI\uNYtKSzVyPUCuNVUyPDFizszNM3zOTXNCVkeHUh?=
CAS-1NVzYPZhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4\IN2lEPTB;MD6xOVQ5OiEQvF2=MnLWV2FPT0WU
D-263MGNWH1V4RVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkDmTWM2OD1yLkG2NFA3KM7:TR?=MonrV2FPT0WU
A253NWnjUlBrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVjJR|UxRTBwMU[xNlgh|ryPMl3pV2FPT0WU
PF-382MkLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF\DTJhKSzVyPUCuNVY4ODZizszNNHTifW1USU6JRWK=
CESSMYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWfJR|UxRTBwMUewOkDPxE1?MWTTRW5ITVJ?
MZ2-MELM2rRS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXnaV|FSUUN3ME2wMlE4PTV7IN88US=>NX7LbZhzW0GQR1XS
HELMYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVT4[2hYUUN3ME2wMlE5PTF5IN88US=>NIHkPIRUSU6JRWK=
D-392MGMo[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXnMWVdqUUN3ME2wMlE6OTF3IN88US=>MUnTRW5ITVJ?
SK-LMS-1MoqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MojyTWM2OD1yLkG5N|A{KM7:TR?=NFvrU2VUSU6JRWK=
GI-ME-NNWDnVVVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXLJR|UxRTBwMUmzNFYh|ryPM1O0cHNCVkeHUh?=
LB831-BLCNYXBNpJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX\wd|AyUUN3ME2wMlE6OzRizszNMny1V2FPT0WU
DU-4475M2DhXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVLJR|UxRTBwMUm2OVgh|ryPMoDWV2FPT0WU
IST-SL1M{L1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4fsVWlEPTB;MD6yNFA6PCEQvF2=NIP0XJpUSU6JRWK=
GAKMULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIfLd4hKSzVyPUCuNlA2OzRizszNNVP2PGxjW0GQR1XS
EW-1NG\OS3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3jXfWlEPTB;MD6yNVA1PyEQvF2=MWjTRW5ITVJ?
LAMA-84MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYDJR|UxRTBwMkG4OVEh|ryPMnKyV2FPT0WU
SK-UT-1M17SUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2m2OWlEPTB;MD6yNlA1QSEQvF2=M3zUVHNCVkeHUh?=
VA-ES-BJNFj2ZZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWDJR|UxRTBwMkKyOVch|ryPNGP3elBUSU6JRWK=
ACNMX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXHaW3YyUUN3ME2wMlIzPjN6IN88US=>MmPnV2FPT0WU
SK-PN-DWNF64XYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2DtNWlEPTB;MD6yN|E6KM7:TR?=MWPTRW5ITVJ?
HD-MY-ZMkS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmjnTWM2OD1yLkKzN|A{KM7:TR?=NE\pUGdUSU6JRWK=
LB373-MEL-DNF\vZVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUP6cZUyUUN3ME2wMlI1OTl6IN88US=>NVfkblNEW0GQR1XS
COLO-829MnLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2PRRmlEPTB;MD6yOFI2PyEQvF2=Ml36V2FPT0WU
ES8M1rYSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH\Qfo5KSzVyPUCuNlQ4PjNizszNNVzVZo51W0GQR1XS
RXF393NET6dJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYLa[VNZUUN3ME2wMlI2ODF3IN88US=>NIXpbW5USU6JRWK=
TK10M3KwTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVfZbGx6UUN3ME2wMlI2PDN3IN88US=>NV;SU5MzW0GQR1XS
LOUCYNH74SVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVXJR|UxRTBwMkW0OVYh|ryPNEnRSpRUSU6JRWK=
MZ7-melMn\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVSwNnlqUUN3ME2wMlI3Ozd2IN88US=>M{TaOXNCVkeHUh?=
CP67-MELNGW3OmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWqwXpRrUUN3ME2wMlI3PzNizszNMmPrV2FPT0WU
C2BBe1M4DYSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYLJR|UxRTBwMke5NFch|ryPNVrBVoE5W0GQR1XS
K052NV7rbmpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEnSTmdKSzVyPUCuNlg6QSEQvF2=NXHjVFhOW0GQR1XS
MOLT-16MoLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHXJbVBKSzVyPUCuNlk2OjRizszNNUC0enpUW0GQR1XS
KNS-81-FDNFPyPGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mln0TWM2OD1yLkOwN|I{KM7:TR?=NIPW[2lUSU6JRWK=
CMKM{n5[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVHJR|UxRTBwM{GxNkDPxE1?M17ZN3NCVkeHUh?=
LAN-6NFPEWoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmfNTWM2OD1yLkOxN{DPxE1?NX\VRlVYW0GQR1XS
KLENF7lN|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYHJR|UxRTBwM{GzNFYh|ryPNELsUVdUSU6JRWK=
NCCITNWW2eWNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF7HcY5KSzVyPUCuN|E4QDNizszNMl;vV2FPT0WU
HHMX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVvJR|UxRTBwM{K4PVch|ryPNHzq[lJUSU6JRWK=
TE-8NWXGNZFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUjSfoZxUUN3ME2wMlM1Ojd7IN88US=>M3S0fXNCVkeHUh?=
GDM-1NHPjVItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV7pfWw2UUN3ME2wMlM2OTB2IN88US=>MXrTRW5ITVJ?
NCI-H747MlyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVvJR|UxRTBwM{exNFMh|ryPM2S0bnNCVkeHUh?=
NCI-H1092MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NELF[GtKSzVyPUCuN|g5PDRizszNM2HwVnNCVkeHUh?=
8-MG-BAM1nNRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUjJR|UxRTBwM{m4N|ch|ryPNVu4XVlqW0GQR1XS
NB17NXfWb2ZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnnaTWM2OD1yLkSyPVch|ryPNHm4SIdUSU6JRWK=
LC4-1M4TneWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoLzTWM2OD1yLkSzOlA4KM7:TR?=M2nlW3NCVkeHUh?=
TE-1NGLV[ZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXzJR|UxRTBwNEWxNVkh|ryPNWT4N2o2W0GQR1XS
KALS-1MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVHMVnVCUUN3ME2wMlQ3PTh2IN88US=>MnrrV2FPT0WU
CCRF-CEMNHnrfHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHPMemlKSzVyPUCuOFc3PzRizszNMlzwV2FPT0WU
OS-RC-2MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlK1TWM2OD1yLkS3PVczKM7:TR?=NEC4TZlUSU6JRWK=
A704M{LsdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXv5eotFUUN3ME2wMlQ5Pjl{IN88US=>M3HyZnNCVkeHUh?=
BB49-HNCMX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXjOcVI6UUN3ME2wMlQ6ODl4IN88US=>Mor1V2FPT0WU
EVSA-TNUfuUlRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGDLdJNKSzVyPUCuOFk6OTFizszNMnG0V2FPT0WU
Mo-TM3HhVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH7UNXZKSzVyPUCuOVE4PjJizszNM13hZXNCVkeHUh?=
MONO-MAC-6Mo\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M32yOmlEPTB;MD61N|YyOSEQvF2=M3rGWnNCVkeHUh?=
BB65-RCCNETGN2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIHOd4NKSzVyPUCuOVY5OTFizszNNWHSdZBQW0GQR1XS
NCI-H1882M1XPNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUjJR|UxRTBwNUmwN|Yh|ryPNGSx[GpUSU6JRWK=
TE-9NV22O5R5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4rRZmlEPTB;MD62NVA{OyEQvF2=M3TMTXNCVkeHUh?=
NCI-H2126MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MljxTWM2OD1yLk[yOlY6KM7:TR?=NGn5[ZFUSU6JRWK=
SF268NY\6XY1ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkT2TWM2OD1yLk[1OlQyKM7:TR?=MlHFV2FPT0WU
SW872Mmr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVPqOYhzUUN3ME2wMlY2PzJ7IN88US=>MXXTRW5ITVJ?
LS-513MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWq0dHpLUUN3ME2wMlY3PzVzIN88US=>MXjTRW5ITVJ?
NCI-H1355NXv3TXpMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkLXTWM2OD1yLk[4OlE6KM7:TR?=NU\LZ4JUW0GQR1XS
BL-70NGHYTYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlK1TWM2OD1yLk[5N|g5KM7:TR?=MU\TRW5ITVJ?
NCI-SNU-5NUPk[GhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1fJUGlEPTB;MD62PVU1PSEQvF2=MmDnV2FPT0WU
SNU-C2BMWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkLHTWM2OD1yLkewO|M6KM7:TR?=M{H6fXNCVkeHUh?=
GB-1M4T1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFTOOVFKSzVyPUCuO|IyOjRizszNM4fOXHNCVkeHUh?=
CTB-1MlTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NE\Gc5dKSzVyPUCuO|c6PTVizszNNF;hSItUSU6JRWK=
BeckerMWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXTMPVlsUUN3ME2wMlc6PjJzIN88US=>M1\R[3NCVkeHUh?=
KM12NHm0SHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUPQOpd6UUN3ME2wMlg2PDZ4IN88US=>NWTRS3dbW0GQR1XS
ES7Mk\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoW4TWM2OD1yLki5OlUh|ryPMl6zV2FPT0WU
COLO-684M2HPPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{nNcGlEPTB;MD65NFY2QCEQvF2=MoHuV2FPT0WU
HCC2998M4PsUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mmj6TWM2OD1yLkmzPFU1KM7:TR?=NGHiN3FUSU6JRWK=
TE-10NX65fHJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1P2NmlEPTB;MD65OlQ{KM7:TR?=MlfiV2FPT0WU
SF126M1HLe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVm2clVuUUN3ME2wMlk5QTdzIN88US=>MorNV2FPT0WU
EKVXM17pXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlXoTWM2OD1zLkCzOFQzKM7:TR?=NFi0Xo5USU6JRWK=
KARPAS-45MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWLJR|UxRTFwMESwNVYh|ryPM2WyOnNCVkeHUh?=
KGNMVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnXmTWM2OD1zLkC1NFQ2KM7:TR?=M3fIT3NCVkeHUh?=
ES1NUXscZR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MorTTWM2OD1zLkC3PVIyKM7:TR?=MX7TRW5ITVJ?
L-540Mn3ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHP5TXhKSzVyPUGuNVE5OzlizszNMkPXV2FPT0WU
KURAMOCHINGTn[IZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4rDXGlEPTB;MT6xNlM4PCEQvF2=NUTl[mg5W0GQR1XS
LU-65MoHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIjaSmxKSzVyPUGuNVI4PTNizszNMWTTRW5ITVJ?
MFH-inoNIrJemlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX3p[mF5UUN3ME2xMlE4PTBzIN88US=>NGX0UmRUSU6JRWK=
NCI-H23NV3ZSHhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUfJR|UxRTFwMkC0NUDPxE1?MVTTRW5ITVJ?
IA-LMNIPwelBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2DWOGlEPTB;MT6yOFEyPiEQvF2=NIi5ZlZUSU6JRWK=
PSN1MojzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVLJR|UxRTFwMkewNVYh|ryPMnPPV2FPT0WU
NCI-H719MmXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3Tsc2lEPTB;MT6yO|QyOSEQvF2=NU\HdZFHW0GQR1XS
SW684MlnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXvJR|UxRTFwMki2OVkh|ryPNUTsU5MxW0GQR1XS
HCE-4M2PaRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MofhTWM2OD1zLkOwNlIyKM7:TR?=MUDTRW5ITVJ?
EW-16MnHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2nBR2lEPTB;MT6zNVM1PyEQvF2=NEjYZopUSU6JRWK=
NCI-H128NWDSUZBvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mk[1TWM2OD1zLkO1PFE1KM7:TR?=NIDxNY1USU6JRWK=
HC-1NETCVIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3q3dGlEPTB;MT6zPFE4KM7:TR?=NGrFZ2NUSU6JRWK=
IST-MES1NHLBNFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mnj4TWM2OD1zLkSwNlA5KM7:TR?=Ml;mV2FPT0WU
RajiMn3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEDSdZRKSzVyPUGuOFE5PSEQvF2=M1TVb3NCVkeHUh?=
DMS-114NF\OTphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWHpeJY6UUN3ME2xMlQ1PTN7IN88US=>MkXTV2FPT0WU
GI-1M1Psc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX2wS|R2UUN3ME2xMlQ4OTNzIN88US=>NXzCVmY1W0GQR1XS
NCI-H2081MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX60S4hwUUN3ME2xMlU2OTl4IN88US=>NX7wNoNvW0GQR1XS
LC-1FM1m2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUfvbnp1UUN3ME2xMlU2OTl6IN88US=>MmniV2FPT0WU
NCI-H2227NF;qR21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYnJR|UxRTFwNkG1OlEh|ryPMYXTRW5ITVJ?
D-502MGMl[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4DxWWlEPTB;MT62O|IyOSEQvF2=MU\TRW5ITVJ?
NCI-H2141NG\PdIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH2zeoVKSzVyPUGuOlc{OTdizszNMle0V2FPT0WU
LS-411NMXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHrqbpRKSzVyPUGuOlk5ODdizszNNIK3dYZUSU6JRWK=
SU-DHL-1MoXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlnaTWM2OD1zLkexNlgyKM7:TR?=Mli5V2FPT0WU
BB30-HNCMUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mln6TWM2OD1zLkeyOlg2KM7:TR?=MV;TRW5ITVJ?
TE-15NVHDe4JIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUPFNYhXUUN3ME2xMlkzOzd|IN88US=>Mn72V2FPT0WU
JVM-3MkKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWLJR|UxRTFwOUO5NFQh|ryPNUnkOVFFW0GQR1XS
IST-SL2M2L2dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXfJR|UxRTJwMEGyOVIh|ryPNWDSSHJFW0GQR1XS
EW-18M1TFWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn\2TWM2OD1{LkCyN|M4KM7:TR?=MXfTRW5ITVJ?
DJM-1NYO3PI1wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3izcmlEPTB;Mj6wNlU2OiEQvF2=NGTFR|lUSU6JRWK=
no-11MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MojiTWM2OD1{LkCzNVA1KM7:TR?=NFnidZZUSU6JRWK=
QIMR-WILNHHGcHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGnLN2NKSzVyPUKuNVY4PjJizszNMUXTRW5ITVJ?
MC-CARMkfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoToTWM2OD1{LkKyPVUh|ryPMlj1V2FPT0WU
KM-H2MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUjJR|UxRTJwMkmwOFMh|ryPNGP0PZVUSU6JRWK=
ECC12M3XxXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUTJR|UxRTJwM{e5OEDPxE1?M3XPe3NCVkeHUh?=
HCE-TM4C1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV\JR|UxRTJwNES4PFMh|ryPMmDzV2FPT0WU
MFM-223MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYrJR|UxRTJwNUC4O|Eh|ryPNFjMV2xUSU6JRWK=
SW982NFzSVYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MW\JR|UxRTJwNUG0PEDPxE1?MVzTRW5ITVJ?
KG-1MoTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1j3RmlEPTB;Mj64PFc6OSEQvF2=NHTjWmRUSU6JRWK=
ES4M{TSUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIfYVHRKSzVyPUOuNFYyOTFizszNM2Wx[nNCVkeHUh?=
SCC-3MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH\rdFdKSzVyPUOuNVA5PDhizszNM{W0dXNCVkeHUh?=
RH-1MoPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYrJR|UxRTNwM{i3OFgh|ryPNV\JW2hQW0GQR1XS
NCI-H748MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVztb4Z[UUN3ME2zMlQ1OjZ4IN88US=>M1Pl[3NCVkeHUh?=
HCC2218MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlX5TWM2OD1|LkS2PVM4KM7:TR?=NWXJPZpZW0GQR1XS
MEG-01NF71fm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1frfGlEPTB;Mz61PVY5KM7:TR?=NXHDfWR5W0GQR1XS
NB12NEDLOHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIP5OHpKSzVyPUOuOVk5QDhizszNNGXFNpZUSU6JRWK=
SNB75NFf4VWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXznW3NJUUN3ME2zMlYxOTB|IN88US=>NUTKN2Q6W0GQR1XS
KMS-12-PEMV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXrJR|UxRTNwNke3NlMh|ryPMXvTRW5ITVJ?
SKM-1NFH2fm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVfJR|UxRTNwN{GzO|Yh|ryPNV[4cJhpW0GQR1XS
COLO-320-HSRMVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2m5WWlEPTB;Mz63OVY{PCEQvF2=M4H3VnNCVkeHUh?=
NKM-1M3zJTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX7xbJR3UUN3ME2zMlc4Ozd6IN88US=>NHu5RYVUSU6JRWK=
TE-6MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4HsVmlEPTB;Mz65OFU3OSEQvF2=Mn[yV2FPT0WU
D-336MGMlnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVnEdJBYUUN3ME20MlAyOTZ4IN88US=>MVnTRW5ITVJ?
NCI-H1650MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGTo[5VKSzVyPUSuNVU4QTdizszNNX3vd25qW0GQR1XS
ES3NIHheHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYr4RYt2UUN3ME20MlMzQDJ2IN88US=>NX\yTVJGW0GQR1XS
YTMnewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVnJR|UxRTRwM{W0NlQh|ryPNFXGXI9USU6JRWK=
ES5NX24Wmw4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4LyZmlEPTB;ND60NFI2PSEQvF2=MoTDV2FPT0WU
LB647-SCLCNELVPWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVHJR|UxRTRwNU[zNFgh|ryPMlHRV2FPT0WU
HAL-01NXjOdmpiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3HCcGlEPTB;ND61O|A{PCEQvF2=MkLmV2FPT0WU
LP-1Mnj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NG\1cFNKSzVyPUSuO|I{PzFizszNMmrRV2FPT0WU
BC-1Mk\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4PFfGlEPTB;NT6wNFQ1PyEQvF2=NFL3PI1USU6JRWK=
EB-3NFLmXGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkK2TWM2OD13LkCzNFQyKM7:TR?=M2DIOXNCVkeHUh?=
GT3TKBNYTJdohIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWDKbWJmUUN3ME21MlE4PjZ{IN88US=>NGHVUmhUSU6JRWK=
NCI-H209NXrkT2JyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYHJR|UxRTVwMUmzOVIh|ryPM3\vZ3NCVkeHUh?=
BT-474NYr1S|dHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUjJR|UxRTVwMkOxNFIh|ryPM3TQWnNCVkeHUh?=
RKOM1P3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3q2UGlEPTB;NT6yN|QzOiEQvF2=NWK0WZNYW0GQR1XS
SIMAMoXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEPhTo1KSzVyPUWuN|A4PjVizszNMVXTRW5ITVJ?
RLM{XkO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWnJR|UxRTVwM{e1OFEh|ryPMnjOV2FPT0WU
GCIYMYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHjuWWxKSzVyPUWuOFczOzZizszNMoOxV2FPT0WU
Calu-6NWfy[oxnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVXJR|UxRTVwNkKyJO69VQ>?M2TvNXNCVkeHUh?=
ALL-PONGe2S5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWLJR|UxRTVwNkO3PVUh|ryPM4K0PHNCVkeHUh?=
ARH-77NUS2UopiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXT6SpQyUUN3ME21MlY4ODh5IN88US=>M{fUfHNCVkeHUh?=
A4-FukM2HoPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoDETWM2OD14LkC4NVE5KM7:TR?=M4DtW3NCVkeHUh?=
NCI-H1581NFXZVlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWTJR|UxRTZwMkO4OFkh|ryPNHLabFhUSU6JRWK=
HUTU-80NUXsTJZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX\yTYRUUUN3ME22MlM3QDl5IN88US=>MWLTRW5ITVJ?
TGWM2HwOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MljWTWM2OD14LkS1OVk{KM7:TR?=M3PWOXNCVkeHUh?=
SK-N-FINHTnTXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmT3TWM2OD14LkS1PFU1KM7:TR?=MWjTRW5ITVJ?
U-266Ml7nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXzrSnB6UUN3ME22MlUyQTJ4IN88US=>MWHTRW5ITVJ?
EM-2MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFrnZpNKSzVyPU[uOlcxQTlizszNNXP3b5hEW0GQR1XS
NMC-G1MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYnJR|UxRTZwN{G4PVUh|ryPNELiT4JUSU6JRWK=
KASUMI-1MlPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmO2TWM2OD14Lki0O|g4KM7:TR?=NE\LOIxUSU6JRWK=
NALM-6NUHObmt7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYLCNIp3UUN3ME22Mlg3PzV2IN88US=>NWnE[mtCW0GQR1XS
OCI-AML2MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn\nTWM2OD15LkCwN|I3KM7:TR?=MVXTRW5ITVJ?
SHP-77MlHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlHSTWM2OD15LkKyOFMh|ryPNGnEU3JUSU6JRWK=
NOMO-1NVPGXnJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1PDcmlEPTB;Nz6yOFI2PCEQvF2=MX3TRW5ITVJ?
SK-N-DZNEnzdVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUi4O|FsUUN3ME23MlcyODh7IN88US=>M3vS[nNCVkeHUh?=
LB1047-RCCNGrtNZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH[zZ|BKSzVyPUeuO|IzOzFizszNNXqxRpN1W0GQR1XS
MZ1-PCNGn0dHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlryTWM2OD15Lki2OVU5KM7:TR?=MVHTRW5ITVJ?
NB10Mn22S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHnkSZlKSzVyPUeuPVk2PTZizszNM4mxZXNCVkeHUh?=
RL95-2NEO5RVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVrJR|UxRThwMUC4OFIh|ryPMVzTRW5ITVJ?
OMC-1MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NETEOVRKSzVyPUiuOVIyQTFizszNMVPTRW5ITVJ?
D-283MEDM3fReGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3fC[WlEPTB;OD65NVcyQSEQvF2=MWXTRW5ITVJ?
MC116MnXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2j1PWlEPTB;OD65O|k1KM7:TR?=MoLPV2FPT0WU
SJSA-1NWHncJJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXrJenFLUUN3ME25MlA6ODlzIN88US=>NHG5[FRUSU6JRWK=
JiyoyeP-2003M4LWU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{DscGlEPTB;OT6yPVMyPyEQvF2=MVXTRW5ITVJ?
IST-MEL1M1\z[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYn1fFlLUUN3ME25Mlc1OTl6IN88US=>MlWyV2FPT0WU
CTV-1MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlLRTWM2OD1zMD6wPVc6KM7:TR?=MnTPV2FPT0WU
NH-12MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXS5dG53UUN3ME2xNE4zPDN|IN88US=>NVnnXVVNW0GQR1XS
CA46M1;lS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWXJR|UxRTFyLkO2NUDPxE1?NI[1No9USU6JRWK=
NCI-SNU-1MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGXj[YVKSzVyPUGwMlQ6PjlizszNMVfTRW5ITVJ?
SCLC-21HM371OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlfaTWM2OD1zMD62OVk3KM7:TR?=MlXjV2FPT0WU
EC-GI-10NUDqcmgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{fQV2lEPTB;MUCuO|A{OSEQvF2=NUSx[5p1W0GQR1XS
SRNY\mSHh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEf4WotKSzVyPUGxMlAyQDVizszNM1TldnNCVkeHUh?=
NCI-H1648M3Lq[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVfvV|dJUUN3ME2xNU4xQTZ3IN88US=>MYjTRW5ITVJ?
TGBC1TKBNXvmUoVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYrJR|UxRTFzLkSxNFIh|ryPNWjVbHRQW0GQR1XS
EW-11MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3;xOmlEPTB;MUGuOVE5PiEQvF2=NV\3VFd1W0GQR1XS
SK-MM-2M2f3VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NW\FRYdNUUN3ME2xNU45ODZzIN88US=>MnHOV2FPT0WU
NCI-H524MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmjWTWM2OD1zMT65PFIzKM7:TR?=NIWxVHRUSU6JRWK=
NOS-1MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUTJR|UxRTF{LkCzOFUh|ryPNYXVR3Q1W0GQR1XS
AM-38M4fBc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NE\zNY9KSzVyPUGyMlU3OzNizszNMWDTRW5ITVJ?
A498MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NInT[HRKSzVyPUGyMlcxPjlizszNMV\TRW5ITVJ?
KARPAS-422NIr5SFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NI\3colKSzVyPUGyMlc1QTZizszNM2\oSHNCVkeHUh?=
LU-139NGLZVllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVP4RWZvUUN3ME2xNk46ODJ4IN88US=>M37HTnNCVkeHUh?=
COR-L88MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV:1dIpLUUN3ME2xNk46Ozh{IN88US=>NXfaPGQ5W0GQR1XS
K5NITh[o1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYnJR|UxRTF{Lkm0OlIh|ryPNYrzN45DW0GQR1XS
NB13M1e4XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoPaTWM2OD1zMj65O|g{KM7:TR?=MlvCV2FPT0WU
MRK-nu-1NWHoS5FqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGSxVYZKSzVyPUGzMlE6PSEQvF2=MoDXV2FPT0WU
MHH-NB-11M3zUdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mln2TWM2OD1zMz6yPVAzKM7:TR?=MkDmV2FPT0WU
KU812Mk\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF7EN21KSzVyPUGzMlYyOjRizszNMlrCV2FPT0WU
TE-12MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVvJR|UxRTF|Lk[5PVQh|ryPMULTRW5ITVJ?
NCI-N87MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUW4fndEUUN3ME2xN{44OzZizszNM3[3VHNCVkeHUh?=
EB2MnzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFnXT3RKSzVyPUGzMlg2ODVizszNMmC1V2FPT0WU
DBNIXiNlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2[5XGlEPTB;MUOuPVg5PSEQvF2=Mnn3V2FPT0WU
697M4LKdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFu3fVVKSzVyPUG0MlQ2OTFizszNNHPLdIFUSU6JRWK=
MSTO-211HMo\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml7pTWM2OD1zND63OFQ5KM7:TR?=MmXtV2FPT0WU
JVM-2MlTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIrWWZlKSzVyPUG0Mlc4OzVizszNM2nIRXNCVkeHUh?=
COLO-824M1TiWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlLCTWM2OD1zND63PVk1KM7:TR?=M2HTXHNCVkeHUh?=
BC-3M3y2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NELkd4RKSzVyPUG1MlM6QCEQvF2=MVLTRW5ITVJ?
BOKUNHzQeHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NET5N|FKSzVyPUG1Mlk3ODhizszNMo\GV2FPT0WU
GOTOMWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV3JR|UxRTF4Lkm2NVch|ryPMmSyV2FPT0WU
HCC2157MkjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mnf6TWM2OD1zNz60O|U2KM7:TR?=NI\ETIlUSU6JRWK=
LS-1034NHLTWmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYPJR|UxRTF5Lk[4NVgh|ryPNIHCWYtUSU6JRWK=
CAL-148Mk\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHXoVWhKSzVyPUG3Mlk4QTZizszNNEXxOXFUSU6JRWK=
MOLT-4NXPu[Zh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEGzeFVKSzVyPUG4MlgzODhizszNMn\0V2FPT0WU
DaudiNEHLTIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NECxT2lKSzVyPUG4MlkzOzFizszNMYrTRW5ITVJ?
J-RT3-T3-5M3W0O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXTJR|UxRTF7LkSwOlYh|ryPMlLvV2FPT0WU
KMOE-2M4PDe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3W3[mlEPTB;MUmuOlQ5OiEQvF2=MVPTRW5ITVJ?
HL-60M1\Nemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mmn1TWM2OD1{MD6xPVY2KM7:TR?=M4\IfnNCVkeHUh?=
P31-FUJMVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXjJR|UxRTJyLkS3OVMh|ryPNHz2b2ZUSU6JRWK=
IM-9MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3fPd2lEPTB;MkCuOlIzPCEQvF2=MXPTRW5ITVJ?
HDLM-2NIrCVlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVrJR|UxRTJyLki4NlEh|ryPNWHUdXhzW0GQR1XS
NCI-H1304MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYXJR|UxRTJzLkCzNVEh|ryPNXHFUnp[W0GQR1XS
NCI-H345M3HGU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmDpTWM2OD1{MT6wOlQ{KM7:TR?=NUfq[opVW0GQR1XS
RPMI-6666M3i5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1fUZmlEPTB;MkGuN|YxOiEQvF2=MlztV2FPT0WU
GR-STM3PGdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYT5PIJEUUN3ME2yNU41OTdizszNMnPFV2FPT0WU
CHP-126M1\i[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXzJR|UxRTJzLk[xPFEh|ryPMl\nV2FPT0WU
EHEBM17nW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3fQSGlEPTB;MkGuOlc{OSEQvF2=NFTx[lBUSU6JRWK=
CPC-NNVLGWHRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3POfmlEPTB;MkSuNFIxOSEQvF2=NYXpNYdxW0GQR1XS
NB1MmjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{e1fGlEPTB;MkSuOlk{QSEQvF2=NVPDO41zW0GQR1XS
LS-123NHfNWlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYfZSGpiUUN3ME2yOE46ODF{IN88US=>NYS5RoZPW0GQR1XS
ST486NXLFUGdFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3W3bGlEPTB;MkWuNVEyOyEQvF2=NH\PfJpUSU6JRWK=
NCI-H1963MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVLyXG9qUUN3ME2yOk4xPjJ|IN88US=>MVjTRW5ITVJ?
U-87-MGMkPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn3rTWM2OD1{Nj63OlQ1KM7:TR?=MWDTRW5ITVJ?
COR-L279NULpc2Z5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYTH[XdMUUN3ME2yOk44QTJ{IN88US=>M2nkdnNCVkeHUh?=
LU-165MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUTDS3dYUUN3ME2yPE4xQDZzIN88US=>M1HxUHNCVkeHUh?=
COLO-800NVLOc2NuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlThTWM2OD1{OD6yPVU3KM7:TR?=NVvZRW1XW0GQR1XS
ETK-1MnLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mmi4TWM2OD1{OD6zOFQ3KM7:TR?=MUPTRW5ITVJ?
LNCaP-Clone-FGCNF3ydnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkGxTWM2OD1{OT65NlgyKM7:TR?=NHm5VXRUSU6JRWK=
SIG-M5NXTWN3E3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXPJR|UxRTNyLke5OVIh|ryPNUH5eZJxW0GQR1XS
NB6NGLhenlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV3XXHE3UUN3ME2zNE46PTB|IN88US=>M3jxdXNCVkeHUh?=
NCI-H2107NIrrSYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2jiW2lEPTB;M{GuNlM{QCEQvF2=M1HIVHNCVkeHUh?=
SNU-C1MoXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkTZTWM2OD1|MT6zNVI3KM7:TR?=M3vySXNCVkeHUh?=
JARM4m5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUj0b4FJUUN3ME2zNU4{Pzl7IN88US=>M17SRXNCVkeHUh?=
L-363MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF;0NWVKSzVyPUOyMlIyPDRizszNMmDJV2FPT0WU
EW-24M3fHSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGTjfmpKSzVyPUOyMlM1PzRizszNMX;TRW5ITVJ?
NB69NXPLN3hrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVLWNXIyUUN3ME2zN{43PDV2IN88US=>M{m0ZXNCVkeHUh?=
EW-13MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYnDXYtMUUN3ME2zN{45QTZ7IN88US=>M3roV3NCVkeHUh?=
Ramos-2G6-4C10MmP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXzISYdQUUN3ME2zOE4zQTl|IN88US=>M{nQSHNCVkeHUh?=
TE-11NWCycolWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVHicHd5UUN3ME2zOE41QDJ{IN88US=>NX;yXo43W0GQR1XS
L-428NYTnb5VZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIjhfWlKSzVyPUO0Mlc2OzZizszNMYHTRW5ITVJ?
KP-N-YNNUn5bIJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH\xU5RKSzVyPUO0MlkxPTdizszNMoLMV2FPT0WU
CGTH-W-1M1nhRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVfJR|UxRTN4LkmwOFgh|ryPNYHFSVVWW0GQR1XS
K-562NHvJcpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkLsTWM2OD1|Nz6wPFY1KM7:TR?=MV7TRW5ITVJ?
NCI-H1299M1LTOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1nKXWlEPTB;M{iuNVYxOyEQvF2=MVvTRW5ITVJ?
RCC10RGBNFSyO|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWfJR|UxRTN6LkKwPFMh|ryPNH\LS4hUSU6JRWK=
NCI-SNU-16NYK1Z|k{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV;JR|UxRTN6LkW2OVMh|ryPNXz5XWtZW0GQR1XS
LC-2-adM{HDe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlfxTWM2OD1|OT60N|M4KM7:TR?=NY[0T2hmW0GQR1XS
MHH-PREB-1MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXLxWm5YUUN3ME2zPU44Ozh6IN88US=>M2LaWXNCVkeHUh?=
NCI-H64NYTaS|lQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmfETWM2OD12MD6wPVQ5KM7:TR?=MUnTRW5ITVJ?
LB996-RCCMnrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MljRTWM2OD12MD64O|E3KM7:TR?=MofkV2FPT0WU
DELMUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{\1S2lEPTB;NEGuOFQxPSEQvF2=M2\LNnNCVkeHUh?=
MLMANFPLUYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlrsTWM2OD12MT63OVk2KM7:TR?=NIDud3JUSU6JRWK=
SBC-1NWHvbZc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NU[xbnZWUUN3ME20Nk4yQDB4IN88US=>Mn7DV2FPT0WU
MPP-89NYTiOINoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWPIbIN3UUN3ME20Nk42QDd3IN88US=>Mm\YV2FPT0WU
MV-4-11M2TSTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1TqT2lEPTB;NEKuPVA3PyEQvF2=NIfobpdUSU6JRWK=
EoL-1-NEnES2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1TOTWlEPTB;NESuNVU3QCEQvF2=NHvpWXBUSU6JRWK=
CW-2MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGLvbY5KSzVyPUS0Mlg{PDJizszNM4PYSnNCVkeHUh?=
HTNXjL[oZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkHkTWM2OD12NT63NFA4KM7:TR?=M3nTTnNCVkeHUh?=
SW954NV7GNZNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIHDVWJKSzVyPUS3MlQyOjhizszNMVTTRW5ITVJ?
A3-KAWMonES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXj4e2dwUUN3ME20PU45ODZzIN88US=>MkjLV2FPT0WU
TC-YIKMn\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGHieIJKSzVyPUWwMlA{PjNizszNNX;udGkzW0GQR1XS
SW962NF7RVIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{GydWlEPTB;NUSuPFM2PyEQvF2=NUTJcZdFW0GQR1XS
KP-N-RT-BM-1MnvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVHMd2ZqUUN3ME21Ok43PjN6IN88US=>NFG3PWxUSU6JRWK=
NCI-H1395MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFS3OHlKSzVyPUW4MlgyPzJizszNMUDTRW5ITVJ?
RPMI-8402NX3UcFAxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXHJR|UxRTV6Lkm1NlYh|ryPNWrDRYE1W0GQR1XS
SCHMlzkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{TOfGlEPTB;NkCuPVY{QCEQvF2=NYrBeIRtW0GQR1XS
NCI-H2196NWDRdmNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX;JR|UxRTZzLkKzNUDPxE1?MnW5V2FPT0WU
LOXIMVIMmHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M17JXGlEPTB;NkGuPFI3PiEQvF2=MnHPV2FPT0WU
TGBC24TKBMY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXm0S3AxUUN3ME22Nk4yPDlzIN88US=>MmiwV2FPT0WU
SK-MEL-2NXv5OYFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlzlTWM2OD14Mz65PFkzKM7:TR?=MnSwV2FPT0WU
U-698-MMkn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4PVUWlEPTB;NkiuOVY5PyEQvF2=NHrOcYJUSU6JRWK=
NCI-H1522NI\sNlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mnv2TWM2OD14OT6wNFQ4KM7:TR?=NH\6TZJUSU6JRWK=
UACC-812MmfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NInuZldKSzVyPU[5MlUzODlizszNMl7PV2FPT0WU
MHH-CALL-2NFnlcIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYLJR|UxRTdyLkC2JO69VQ>?MkHkV2FPT0WU
NB5M1POSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3vHTWlEPTB;N{CuN|Q3QCEQvF2=M2DldnNCVkeHUh?=
KARPAS-299MkHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3zDO2lEPTB;N{CuOFQ1PyEQvF2=NXfjcZpSW0GQR1XS
NCI-H1694NWDYcZdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXvUeHhtUUN3ME23NU4xOzJizszNMWPTRW5ITVJ?
NCI-H82M36xc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoPYTWM2OD15MT65OVA4KM7:TR?=MVTTRW5ITVJ?
SCC-15MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXLJR|UxRTd{LkO0JO69VQ>?MlLJV2FPT0WU
NCI-H1436NYWyRZhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHLpWFJKSzVyPUeyMlc1PTZizszNNHjVPHFUSU6JRWK=
ATN-1MlzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVfJR|UxRTd2LkWwOUDPxE1?Mmq3V2FPT0WU
RPMI-8866M4WzNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUDpRY8zUUN3ME23OE44PTB7IN88US=>NIjWcmVUSU6JRWK=
HCC1599NYGwVnZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXzmVpluUUN3ME23OE45PzN{IN88US=>MYfTRW5ITVJ?
NCI-H1155M2PvfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVHJR|UxRTd2LkmzOlch|ryPM1fyV3NCVkeHUh?=
DOHH-2M4TPbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIfjbnVKSzVyPUe0Mlk2OTRizszNM3O5TXNCVkeHUh?=
SK-NEP-1NVrUd2x4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4fTTGlEPTB;N{WuNFc2PCEQvF2=NIPmW|lUSU6JRWK=
HCC1187MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4O1[WlEPTB;N{euOlEzOiEQvF2=NIfZfWpUSU6JRWK=
NCI-H322MMXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEO1SopKSzVyPUe4MlM4ODlizszNNF60cWNUSU6JRWK=
NCI-H526MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1K3cWlEPTB;N{iuOVg4PyEQvF2=MYPTRW5ITVJ?
NCI-H2171NH3NdFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWDJR|UxRTd7LkSxN|Yh|ryPMmC1V2FPT0WU
COLO-668NYDjd5V5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1LVbWlEPTB;OEGuOVg5PCEQvF2=M4TreHNCVkeHUh?=
RS4-11MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2P1NGlEPTB;OEKuNlUxPSEQvF2=MWXTRW5ITVJ?
NCI-H716NHTJSJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIXWc3NKSzVyPUiyMlkxPzVizszNNFzDR2pUSU6JRWK=
LU-134-AMonwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4rTT2lEPTB;OEOuNVM2OSEQvF2=MVLTRW5ITVJ?
RPMI-8226NGrwWGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVPJR|UxRTh2LkKxNFch|ryPM1\JRnNCVkeHUh?=
KY821M3HMdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHjsdJNKSzVyPUmxMlY2PTFizszNNEHBRYhUSU6JRWK=
ECC4NISzN4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MU\JR|UxRTl|LkiyOlkh|ryPMoPYV2FPT0WU
EW-3MoTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{LjRmlEPTB;OUSuPVA5OSEQvF2=M2PmfXNCVkeHUh?=
NB7NU\aV|lFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWP1XngzUUN3ME25OU44Pzh4IN88US=>M4TFe3NCVkeHUh?=
NCI-H720MkS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYXJR|UxRTl6LkSwOlEh|ryPMljRV2FPT0WU
NCI-H446M4T0bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYTJR|UxRTl7Lke1PFgh|ryPMXPTRW5ITVJ?
NCI-H889MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXXJR|UxRTFyND6yOFIh|ryPMUfTRW5ITVJ?
EW-22MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEm2UFJKSzVyPUGwOk4yQSEQvF2=MYDTRW5ITVJ?
BV-173NI\zdGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnO3TWM2OD1zMEiuO|I5KM7:TR?=NYTU[4IzW0GQR1XS
WSU-NHLMX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX6wdmxlUUN3ME2xNFkvPjdzIN88US=>M{fLenNCVkeHUh?=
MN-60MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3\hcmlEPTB;MUC5MlY6KM7:TR?=MoLQV2FPT0WU
DG-75MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoK4TWM2OD1zMUOuN|UzKM7:TR?=NEnBdINUSU6JRWK=
DMS-79M4[zZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUjXVJpQUUN3ME2xNVcvOzh{IN88US=>NHLoOplUSU6JRWK=
SK-MEL-1Mn;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWjJR|UxRTFzOD6wNFkh|ryPMn7EV2FPT0WU
DMS-153Ml7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIC1SmlKSzVyPUGyNU44PDVizszNNFj5NFJUSU6JRWK=
NCI-H510AMnLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYXrfWlpUUN3ME2xNlcvOzJizszNMW\TRW5ITVJ?
BE-13NHvvZ2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1qxWmlEPTB;MUO0MlA1PCEQvF2=M17iTXNCVkeHUh?=
KP-N-YSMVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYDTU2pVUUN3ME2xN|kvPzN4IN88US=>NF3mWYhUSU6JRWK=
SUP-T1NFTofoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NInsfnJKSzVyPUG0N{44ODhizszNM2fnNnNCVkeHUh?=
EW-12MnX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF7qbWlKSzVyPUG0OE43QTlizszNMofsV2FPT0WU
NB14MkPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYjJR|UxRTF2Nz6wPFIh|ryPMUHTRW5ITVJ?
MDA-MB-134-VIM2rt[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4jxdGlEPTB;MUS4MlI3QCEQvF2=Mn3jV2FPT0WU
NCI-H1770M3LjUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYfJR|UxRTF3Nj6yO|kh|ryPMlm1V2FPT0WU
TURNGHYeIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVP3OWxiUUN3ME2xOlcvQDdizszNMlPaV2FPT0WU
NCI-H1417NWDhcZZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXvJR|UxRTF6MD6zN|Eh|ryPMVzTRW5ITVJ?
IMR-5M{HOd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHrVRVhKSzVyPUG4NU42PzFizszNNEK5SFRUSU6JRWK=
NCI-H226MmTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1TpOmlEPTB;MUi4Mlg3PiEQvF2=NXjiW2s1W0GQR1XS
NCI-H187NWfmXHVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVvCeIpDUUN3ME2xPVAvODZ2IN88US=>MXPTRW5ITVJ?
SF539MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX:yOm5pUUN3ME2xPVIvPzJ6IN88US=>MU\TRW5ITVJ?
TALL-1NUPLZVhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlzRTWM2OD1zOUiuN|A1KM7:TR?=NVvzeo9NW0GQR1XS
TE-441-TMYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXG0VnhOUUN3ME2xPVkvPzN7IN88US=>MmC4V2FPT0WU
REHNXHlcmRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVjjUJB5UUN3ME2yN|YvPjJ4IN88US=>NX7vfWtDW0GQR1XS
MS-1Mlm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEmxZZJKSzVyPUKzPU4yOjFizszNM1vLbHNCVkeHUh?=
THP-1MmfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXfoemhjUUN3ME2yOlQvPzN6IN88US=>MXHTRW5ITVJ?
NCI-H1838M{[2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2HtWmlEPTB;MkexMlQ2PiEQvF2=M1TrXXNCVkeHUh?=
P30-OHKNEXXdWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH;2ZVFKSzVyPUK4N{45PDdizszNNVvzdJlkW0GQR1XS
C8166NXfRZ5RST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIDLPFlKSzVyPUO0OU4{OzhizszNNYK5PW1IW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Administration of MG-132 effectively rescues the expression levels and plasma membrane localization of dystrophin, β-dystroglycan, α-bdystroglycan, and α-sarcoglycan in skeletal muscle fibers from mdx mice, reduces muscle membrane damage, and ameliorates the histopathological signs of muscular dystrophy. [7] MG-132 treatment significantly reduces immobilization-induced skeletal muscle atrophy in mice, by downregulating the muscle-specific ubiquitin ligases atrogin-1/MAFbx and MuRF-1 mRNA. [8]
Features

Protocol(Only for Reference)

Kinase Assay:

[1]

Measurement of inhibitory activities of MG-132 against 20S proteasome The reaction mixture for the 20S proteasome inhibitory assay contains 0.1 M Tris-acetate, pH 7.0, 20S proteasome, MG-132, and 25 μM substrate dissolved in dimethyl sulfoxide in a final volume of 1 mL. After incuba tion at 37 °C for 15 minutes, the reaction is stopped by the addition of 0.1 mL of 10% SDS and 0.9 mL of 0.1M Tris acetate, pH 9.0. The fluorescence of the reaction products is measured. To determine the IC50 against 20S proteasome, various concentrations of MG-132 are included in the assay mixture.

Cell Assay:

[3]

Cell lines KIM-2, HC11, and ES
Concentrations Dissolved in DMSO, final concentrations ~25 μM
Incubation Time 24, and 48 hours
Method

Cells are exposed to various concentrations of MG-132 for 24, and 48 hours. Supernatant and monolayer cells are harvested by centrifugation and fixed in 70% ethanol in PBS for staining with acridine orange. Equal volumes of cells and acridine orange (5 mg/mL in PBS) are mixed on a microscope slide and examined by fluorescence microscopy. For annexin V analysis, cells are harvested by centrifugation and stained with annexin V and propidium iodide. For cell cycle analysis, cells are rehydrated in PBS at room temperature for 10 minutes, followed by staining with propidium iodide (5 mg/mL). All samples are analyzed using a Coulter Epics XL flow cytometer.

Animal Study:

[7]

Animal Models Male mdx (C57BL/10ScSn DMD mdx) mice
Formulation Dissolved in DMSO, and diluted in PBS
Dosages ~10 μg/kg/day
Administration Injection

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Tsubuki S, et al. J Biochem, 1996, 119(3), 572-576.

[2] Fiedler MA, et al. Am J Respir Cell Mol Biol, 1998, 19(2), 259-268.

view more

Chemical Information

Download MG-132 SDF
Molecular Weight (MW) 475.62
Formula

C26H41N3O5

CAS No. 133407-82-6
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 95 mg/mL (199.73 mM)
Ethanol 95 mg/mL (199.73 mM)
Water <1 mg/mL (<1 mM)
In vivo 1% DMSO+30% polyethylene glycol+1% Tween 80, pH 4 6 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name benzyl (S)-4-methyl-1-((S)-4-methyl-1-((S)-4-methyl-1-oxopentan-2-ylamino)-1-oxopentan-2-ylamino)-1-oxopentan-2-ylcarbamate

Customer Product Validation(9)


Click to enlarge
Rating
Source Nat Cell Biol 2015 17(1), 95-103. MG-132 purchased from Selleck
Method Immunoprecipitation
Cell Lines MDA-MB-231 cells
Concentrations 10 uM
Incubation Time 6 h
Results SIAH2 destabilizes LATS2 through proteasome. SIAH2-mediated LATS2 degradation was inhibited by proteasomal inhibitor MG132, but not by lysosomal inhibitor BA-1. The half-life of LATS2 was shortened by SIAH2.

Click to enlarge
Rating
Source Nucleic Acids Res 2014 42(1), 458-74. MG-132 purchased from Selleck
Method Western blot
Cell Lines HeLa cells
Concentrations 20 uM
Incubation Time 8 h
Results As RMND5A downregulation resulted in a rapid decrease of protein Exportin-5, this effect was partially abolished by the proteasome inhibitor MG132, indicating that RMND5A protect Exportin-5 protein against proteasome degradation.

Click to enlarge
Rating
Source Nucleic Acids Res 2014 42(1), 458-74. MG-132 purchased from Selleck
Method Immunocytochemistry
Cell Lines HeLa cells
Concentrations 20 uM
Incubation Time 8 h
Results It was surprised to observe that Exportin-5 retention in nucleus when its protein levels were downregulated by RMND5A siRNA or miR-138. The proteasome inhibitor MG132 could recover not only Exportin-5 protein levels but also its normal subcellular localization.

Click to enlarge
Rating
Source EMBO Mol Med 2013 5, 397-412. MG-132 purchased from Selleck
Method Western Blot
Cell Lines MEF cells
Concentrations 30 uM
Incubation Time 6 h
Results Treatment of MEF with proteasome inhibitor MG132 resulted in similar increase of steady state levels of intracellular ATZ in both GFP- and TFEB- transfected Cells.

Click to enlarge
Rating
Source Cell Rep 2015 11(9), 1458-73. MG-132 purchased from Selleck
Method Western Blot
Cell Lines A375, Lu1205 cells
Concentrations 5 uM
Incubation Time 10 h
Results MG132 treatment increased JAK1 steady-state levels, masking the effect of RNF125 depletion and partially blocking deregulated JAK1 expression by ectopically expressed RNF125.

Click to enlarge
Rating
Source Plant Physiol 2012 60(1), 118-34. MG-132 purchased from Selleck
Method Immunoblot analysis
Cell Lines Arabidopsis thaliana
Concentrations 100 uM
Incubation Time 12 h
Results These rates of loss were markedly slower in the lrb1-1 lrb2-1 background. Importantly, phyB breakdown was also substantially attenuated upon exposing wild-type seedlings to the proteasome inhibitor MG132, thus implicating the 26S proteasome in particular. MG132 treatment also slightly stabilized phyB levels in lrb1-1 lrb2-1 seedlings, implying that other factors besides LRB1 and LRB2 might also direct phyB breakdown.

Click to enlarge
Rating
Source Toxicol Appl Pharmacol 2015 286(2), 135-41. MG-132 purchased from Selleck
Method Immunofluorescence
Cell Lines γ-H2AX-stained cells
Concentrations 100 uM
Incubation Time 3 h
Results G2 cell cycle arrest usually reflects the formation of genomic damage in the preceding S-phase, which activates checkpoint response upon the entry of cells into G2 phase. Furthermore, MG132-treated cells also had larger amounts of γ-H2AX, as evidenced by the increased staining in individual nuclei .

Click to enlarge
Rating
Source FEBS Lett 2012 586, 3787–3792. MG-132 purchased from Selleck
Method Western Blot
Cell Lines Hela cells
Concentrations
Incubation Time 12 h
Results When GSK-3 (Ser9) degradation was blocked by proteasome inhibitor (MG132), the increased amount of phosphorylated GSK-3 (Ser9) in responding to NOK was more clearly observed in the HeLa-NOK-HA cells (Fig. C).

Click to enlarge
Rating
Source 2012 Dr. Edison DUKE-NUS Graduate Medical School Singapore.. MG-132 purchased from Selleck
Method Western blot
Cell Lines NIH3T3 cells
Concentrations 25 μM
Incubation Time 1-4 h
Results By adding MG132, a proteasome inhibitor, the degradation of Per2 was dramatically decreased within 4 hours treatment.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Proteasome Products

  • VR23

    VR23 is a potent proteasome inhibitor with IC50 of 1 nM, 50-100 nM, and 3 μM for trypsin-like proteasomes, chymotrypsin-like proteasomes, and caspase-like proteasomes, respectively.

  • Calpeptin

    Calpeptin is a potent, cell-permeable calpain inhibitor with ID50 of 52 nM, 34 nM, 138 nM, and 40 nM for Calpain I (porcine erythrocytes), Calpain II (porcine kidney), Papainb, and Calpain I (human platelets), respectively.

  • Marimastat(BB-2516)

    Marimastat (BB-2516) is a broad spectrum matrix metalloprotease (MMP) inhibitor for MMP-9, MMP-1, MMP-2, MMP-14 and MMP-7 with IC50 of 3 nM, 5 nM, 6 nM, 9 nM and 13 nM, respectively. Phase 3.

  • Bortezomib (PS-341)

    Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM in a cell-free assay.

  • Carfilzomib (PR-171)

    Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities.

  • Ixazomib (MLN2238)

    MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM in cell-free assays, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM. Phase 3.

    Features:A first-in-class proteasome inhibitor that has improved pharmacokinetics (PK), pharmacodynamics(PD), and antitumor activity in preclinical studies.

  • ONX-0914 (PR-957)

    ONX-0914 (PR-957) is a potent and selective immunoproteasome inhibitor with minimal cross-reactivity for the constitutive proteasome in a cell-free assay.

    Features:The first highly selective, small molecule inhibitor of the immunoproteasome. Potential use in cancer and autoimmune diseases (e.g. rheumatoid arthritis, inflammatory bowel disease, and lupus).

  • MLN9708

    MLN9708 immediately hydrolyzed to MLN2238, the biologically active form, on exposure to aqueous solutions or plasma. MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/Ki of 3.4 nM/0.93 nM in cell-free assays, less potent to β1 and little activity to β2. Phase 3.

    Features:The 1st oral proteasome inhibitor in early stage clinical trials for Multiple Myeloma.

  • Celastrol

    Celastrol is a potent proteasome inhibitor for the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM.

    Features:A potent antioxidant and anti-inflammatory drug.

  • Oprozomib (ONX 0912)

    Oprozomib (ONX 0912) is an orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM. Phase 1/2.

Recently Viewed Items

Tags: buy MG-132 | MG-132 supplier | purchase MG-132 | MG-132 cost | MG-132 manufacturer | order MG-132 | MG-132 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us